Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study

Patients endure risk and uncertainty when they participate in clinical trials. We previously estimated that 12,217 patient-participants are required to bring a new cancer drug to market. However, many development efforts are aimed at extending the label of already approved drugs. Herein, we estimate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouimet, Charlotte, Hutchinson, Nora, Wang, Catherine, Matyka, Carol, Del Paggio, Joseph C., Kimmelman, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522579/
https://www.ncbi.nlm.nih.gov/pubmed/37752147
http://dx.doi.org/10.1038/s41598-023-42213-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522579/
https://www.ncbi.nlm.nih.gov/pubmed/37752147
http://dx.doi.org/10.1038/s41598-023-42213-y

Ejemplares similares